Theranexus SA (ALTHX) AI Stock Analysis

• Market Cap: €19.88M
• Dividend Yield: N/A
• Average Volume (3M): 107.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: N/A
• EPS Growth: 10.28%
• Country: FR
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 7,758,724
• 10 Day Avg. Volume: 79,636
• 30 Day Avg. Volume: 107,258
• PEG Ratio: 0.04
• Price to Book (P/B): -2.98
• Price to Sales (P/S): 2.16
• P/FCF Ratio: -1.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.50
• Price Target Upside: -4.94% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: €2.50 ▼(-4.94% Downside)

Theranexus SA's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and negative profitability margins. While technical analysis shows positive momentum, the company's valuation is unattractive due to its negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events limits additional insights.

Theranexus SA Business Overview & Revenue Model

Company Description

Theranexus SA (ALTHX) is a biotechnology company focused on the development of innovative therapies for central nervous system (CNS) disorders. It specializes in drug repositioning and leveraging its proprietary platform to enhance the efficacy of existing medications. Theranexus aims to address unmet medical needs in conditions such as neurodegenerative diseases and other CNS-related disorders, utilizing its expertise in both pharmacology and neurology to advance its therapeutic candidates.

How the Company Makes Money

Theranexus generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies, which provide funding for the development of its drug candidates. The company may receive milestone payments based on the achievement of specific development goals, as well as royalties from future sales of approved therapies. Additionally, Theranexus may engage in licensing agreements that allow other companies to utilize its proprietary technology or therapeutic candidates, contributing further to its revenue streams. The company's ability to secure these partnerships and collaborations is critical for its financial sustainability and growth.

Theranexus SA Financial Statement Overview

Summary

Theranexus SA is facing significant financial challenges, with declining revenues, negative profitability margins, and a highly leveraged balance sheet. Cash flow issues further exacerbate the financial instability, highlighting the need for strategic changes to improve financial health and sustainability.

Income Statement

Theranexus SA has experienced declining revenue over the past year, with a negative revenue growth rate of 20%. The company also shows negative margins across the board, including a net profit margin of -77.3% and an EBIT margin of -115.0%, indicating significant challenges in achieving profitability. The gross profit margin is also negative, reflecting cost inefficiencies or high cost of goods sold relative to revenue.

Balance Sheet

The balance sheet reveals a concerning financial structure with a negative stockholders' equity, resulting in a debt-to-equity ratio of -1.73. This indicates that the company is highly leveraged and may face difficulties in meeting its financial obligations. The return on equity is positive at 106.5%, but this is due to the negative equity, which distorts the metric.

Cash Flow

Theranexus SA's cash flow statement shows negative operating and free cash flows, with a free cash flow growth rate of -29.6%. The operating cash flow to net income ratio is -0.92, suggesting that the company is not generating sufficient cash from its operations to cover its net losses. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is marginally better than net income, but still negative.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.28M	296.33K	414.90K	602.00	294.61K
Gross Profit	-333.55K	-4.64M	82.90K	-8.82M	-5.31M
EBITDA	-2.53M	-7.39M	-5.93M	-8.67M	-5.33M
Net Income	-1.77M	-6.83M	-6.57M	-8.15M	-4.80M
Balance Sheet
Total Assets	3.74M	7.24M	12.05M	16.89M	17.47M
Cash, Cash Equivalents and Short-Term Investments	966.59K	4.90M	9.11M	12.53M	11.21M
Total Debt	2.87M	3.64M	4.89M	5.33M	5.71M
Total Liabilities	5.40M	5.02M	6.33M	6.71M	7.19M
Stockholders Equity	-1.66M	2.22M	5.73M	10.18M	10.28M
Cash Flow
Free Cash Flow	-3.40M	-6.40M	-5.41M	-6.40M	-6.00M
Operating Cash Flow	-3.37M	-6.36M	-5.37M	-6.25M	-5.75M
Investing Cash Flow	77.04K	-61.11K	323.53K	-150.62K	-252.05K
Financing Cash Flow	-646.42K	2.22M	1.63M	7.71M	7.69M

Theranexus SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHX, the sentiment is Positive. The current price of 2.63 is above the 20-day moving average (MA) of 2.49, above the 50-day MA of 2.54, and above the 200-day MA of 1.17, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 55.49 is Neutral, neither overbought nor oversold. The STOCH value of 71.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALTHX.

Theranexus SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALTHX	52 Neutral	€19.88M	―	―	―	―	10.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%